Vasculitic Diseases of the Kidney

  • James E. Balow
  • Howard A. AustinIII

Abstract

The systemic vasculitides are a diverse set of immunologically mediated disorders that share certain constitutional features, described clinically as the vasculitic syndrome, and that are distinguished by unique complexes of focal symptoms and signs of inflammation and vascular pathology. Several comprehensive monographs (1–4), textbook chapters (5–8), and review articles (9–12) on the clinical and pathological aspects of systemic and renal vasculitis have been published in the past several years. Patients with systemic vasculitis tend to segregate among medical specialties according to the major organ system involvement, and each specialty creates its own classification system. Disciplines vary in their preferences for the lumping and splitting of vasculitic diseases. Proposals for standardization of criteria for diagnosis and classification of systemic vasculitis have recently appeared (13,14).

Keywords

Systemic Vasculitis Polyarteritis Nodosa Nephrol Dial Transplant Crescentic Glomerulonephritis Pulse Cyclophosphamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Churg A, Churg J: Systemic Vasculitides. Igaku-Shoin, New York, pp 1–389, 1991.Google Scholar
  2. 2.
    Cupps TR, Fauci AS: The Vasculitides. WB Saunders, Philadelphia, pp 1–211, 1981.Google Scholar
  3. 3.
    LeRoy EC, ed: Systemic Vasculitis: The Biological Basis Marcel Dekker, New York, pp 1–583, 1992.Google Scholar
  4. 4.
    Sessa A, Meroni M, Battini G: Renal involvement in systemic vasculitis. Contrib Nephrol 94: 1–205, 1991.Google Scholar
  5. 5.
    Balow JE, Fauci AS: Vasculitic diseases of the kidney. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney, 61h ed. Little, Brown, Boston, pp 1851–1878, 1997.Google Scholar
  6. 6.
    Fauci AS, Leavitt RY: Vasculitis. In: DJ McCarty, WJ Koopman, eds, Arthritis and Allied Conditions: A Textbook of Rheumatology, 12th ed. Lea & Febiger, Philadelphia, pp 1301–1302, 1993.Google Scholar
  7. 7.
    Gaskin G, Pusey CD: Systemic vasculitis. In: JS Cameron, AM Davison, JP Grunfeld, D Kerr, E Ritz, eds, Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, pp 612–636, 1992.Google Scholar
  8. 8.
    Spargo BH, Seymour AE, Ordenez NG: Vasculitis. In: Renal Biopsy Pathology with Diagnostic and Therapeutic Implications. Wiley, New York, pp 205–218, 1980.Google Scholar
  9. 9.
    Balow JE: Renal vasculitis. Curr Opin Nephrol Hypertens 2: 231–237, 1993.PubMedCrossRefGoogle Scholar
  10. 10.
    Cameron JS: The long-term outcome of glomerular diseases. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney, 6th ed. Little, Brown, Boston, pp 1919–1981, 1997.Google Scholar
  11. 11.
    Conn DL: Polyarteritis. Rheum Dis Clin North Am 16: 34 1362, 1990.Google Scholar
  12. 12.
    Falk RJ: ANCA-associated renal disease. Kidney Int 38: 998 1010, 1990.Google Scholar
  13. 13.
    Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot RW, Masi AT, McShane DJ, Michel BA, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ: The American College of Rheumatology 1990 Criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 1065–1067, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al.: Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37: 187–192, 1994.PubMedCrossRefGoogle Scholar
  15. 15.
    Angangco R, Thiru S, Esnault VLM, Short AK, Lockwood CM, Oliveira DBG: Does truly “idiopathic” crescentic glomerulonephritis exist? Nephrol Dial Transplant 9: 630636, 1994.Google Scholar
  16. 16.
    Falk RJ, Hogan S, Carey TS, Jennette JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 113: 656–663, 1990.PubMedCrossRefGoogle Scholar
  17. 17.
    Jennette JC, Falk RJ: The pathology of vasculitis involving the kidney. Am J Kidney Dis 24: 130–141, 1994.PubMedGoogle Scholar
  18. 18.
    Velosa JA: Idiopathic crescentic glomerulonephritis or systemic vasculitis? Mayo Clin Proc 62: 145–147, 1987.PubMedCrossRefGoogle Scholar
  19. 19.
    Mathieson PW, Qasim FJ, Esnault VLM, Oliveira DBG: Animal models of systemic vasculitis. J Autoimmunol 6: 25 1264, 1993.Google Scholar
  20. 20.
    Balow JE: Renal vasculitis. Kidney Int 27: 954–964, 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Fauci AS, Haynes BF, Katz P: The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 89: 660–676, 1978.PubMedCrossRefGoogle Scholar
  22. 22.
    D’Agati V, Chander P, Nash M, Mancilla-Jimenez R: Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 7: 95–110, 1986.PubMedGoogle Scholar
  23. 23.
    Davies DJ, Moran JE, Niall JF, Ryan GB: Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J 285: 606, 1982.CrossRefGoogle Scholar
  24. 24.
    van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1: 425–429, 1985.PubMedCrossRefGoogle Scholar
  25. 25.
    Golden MP, Hammer SM, Wanke CA, Albrecht MA: Cytomegalovirus vasculitis. Case report and review of the literature. Medicine (Baltimore) 73: 246–255, 1994.Google Scholar
  26. 26.
    Sergent JS: Vasculitides associated with viral infections. Clin Rheum Dis 6: 339, 1980.Google Scholar
  27. 27.
    Kallenberg CG, Brouwer E, Weening JJ, Cohen Tervaert JW: Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiologic potential. Kidney Int 46: 1–15, 1994.PubMedCrossRefGoogle Scholar
  28. 28.
    Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 41: 375–383, 1992.PubMedCrossRefGoogle Scholar
  29. 29.
    Falk RJ, Terrell R, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals. Proc Nall Acad Sci USA 87: 4115–4119, 1990.CrossRefGoogle Scholar
  30. 30.
    Jennette JC, Tuttle R, Falk RJ: The clinical, serologic, and immunopathologic heterogeneity of cutaneous leukocytoclastic angiitis. Adv Exp Med Biol 336: 323–326, 1993.PubMedGoogle Scholar
  31. 31.
    Hellman DB, Laing TJ, Petri M, Whiting-O’Keefe Q, Parry GJ: Mononeuritis multiplex: the yield of evaluations for occult rheumatic diseases. Medicine (Baltimore) 67: 145–53, 1988.Google Scholar
  32. 32.
    Camillieri M, Pusey CD, Chadwick VS, Rees AJ: Gastrointestinal manifestations of systemic vasculitis. Q J Med 52: 141–149, 1983.Google Scholar
  33. 33.
    Albert DA, Rimon D, Silverstein MD: The diagnosis of polyarteritis nodosa. I. A literature-based decision analysis approach. Arthritis Rheum 31: 1117–1127, 1988.PubMedCrossRefGoogle Scholar
  34. 34.
    Ewald EA, Griffin D, McCune WJ: Correlation of angiographic abnormalities with disease manifestations andGoogle Scholar
  35. disease severity in polyarteritis nodosa. J Rheumatol 145: 952–956, 1987.Google Scholar
  36. 35.
    Dahlberg PJ, Lockhart JM, Overholt EL: Diagnostic studies for systemic necrotizing vasculitis. Arch Intern Med 149: 16 1165, 1989.Google Scholar
  37. 36.
    Hekali P, Kajander H, Pajari R, Stenman S, Somer T: Diagnostic significance of angiographically observed visceral aneurysms with regard to polyarteritis nodosa. Acta Radiol 32: 143–148, 1991.PubMedCrossRefGoogle Scholar
  38. 37.
    Travers RL, Allison DJ, Brettle RP, Hughes GRV: Polyarteritis nodosa: a clinical and angiographic analysis of 17 cases. Semin Arthritis Rheum 8: 184–199, 1979.PubMedCrossRefGoogle Scholar
  39. 38.
    Cohen RD, Conn DL, Ilstrup DM: Clinical features, prognosis and response to treatment in polyarteritis. Mayo Clin Proc 55: 146–155, 1980.PubMedGoogle Scholar
  40. 39.
    Leib ES, Hibrawi H, Chia D, Blaker RG, Barnett EV: Correlation of disease activity in systemic necrotizing vasculitis with immune complexes. J Rheumatol 8: 258–265, 1981.PubMedGoogle Scholar
  41. 40.
    Sack M, Cassidy JT, Bole GG: Prognostic factors in polyarteritis. J Rheumatol 2: 411–420, 1975.PubMedGoogle Scholar
  42. 41.
    Savage CO, Winearls CG, Evans DJ, Rees Ai, Lockwood CM: Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 56: 467–483, 1985.PubMedGoogle Scholar
  43. 42.
    Serra A, Cameron JS, Turner DR, Hartley B, Ogg CS, Neild GH, Williams DG, Taube D, Brown CB, Hicks JA: Vasculitis affecting the kidney: presentation histopathology and long-term outcome. Q J Med 53: 181–207, 1984.PubMedGoogle Scholar
  44. 43.
    Frohnert PP, Sheps SG: Long-term follow-up study of periarteritis nodosa. Am J Med 43: 8–14, 1967.PubMedCrossRefGoogle Scholar
  45. 44.
    Dayson J, Ball J, Platt R: The kidney in periarteritis nodosa. Q J Med 17: 175–202, 1948.Google Scholar
  46. 45.
    Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic auto-antibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318: 1651–1657, 1988.PubMedCrossRefGoogle Scholar
  47. 46.
    Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, The TH, von dem Borne AEG, Kallenberg CGM: Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 37: 799–806, 1990.CrossRefGoogle Scholar
  48. 47.
    Adu D, Howie AJ, Scott DGI, Bacon PA, McGonigle RJS, Michael J: Polyarteritis and the kidney. Q J Med 62: 221–237, 1987.PubMedGoogle Scholar
  49. 48.
    Coward RA, Hamdy NAT, Shortland JS, Brown CB: Renal polyarteritis: a treatable condition. Nephrol Dial Transplant 1: 31–37, 1986.PubMedGoogle Scholar
  50. 49.
    Fuiano G, Cameron JS, Raftry M, Hartley BH, Williams DG, Ogg CS: Improved prognosis of renal polyarteritis in recent years. Nephrol Dial Transplant 3: 383–391, 1988.PubMedGoogle Scholar
  51. 50.
    Gaskin G, Savage CO, Ryan JJ, Jones S, Rees AJ, Lockwood CM, Pusey CD: Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 6: 689–694, 1991.PubMedCrossRefGoogle Scholar
  52. 51.
    Wilkowski MJ, Velosa JA, Holley KE, Offord KP, Chu C-P, Torres VE, McCarthy JT, Donadio JV Jr, Wagoner RD: Risk factors in idiopathic renal vasculitis and glomerulonephritis. Kidney Int 36: 1133–1141, 1989.PubMedCrossRefGoogle Scholar
  53. 52.
    Churg J: Nomenclature of vasculitic syndromes: a historical perspective. Am J Kidney Dis 18: 148–153, 1991.PubMedGoogle Scholar
  54. 53.
    Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, Peel AC, Wood JB: Wegener’s granuloma: a series of 265 British cases seen between 1975 and 1985. Q J Med 83: 427–438, 1992.PubMedGoogle Scholar
  55. 54.
    Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76–85, 1983.PubMedCrossRefGoogle Scholar
  56. 55.
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488498, 1992.Google Scholar
  57. 56.
    Woodworth TG, Abuelo JG, Austin HA III, Esparza A: Severe glomerulonephritis with late emergence of classic Wegener’s granulomatosis. Medicine (Baltimore) 66: 18 1191, 1987.Google Scholar
  58. 57.
    Kerr GS, Fleischer TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS.: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 36: 365–371, 1993.PubMedCrossRefGoogle Scholar
  59. 58.
    Bindi P, Mougenot B, Mentre F, Noel LH, Peraldi MN, Vanhille P, Lesavre P, Mignon F, Ronco PM: Necrotizing crescentic glomerulonephritis without significant immune deposits: a clinical and serological study. Q J Med 86: 55–68, 1993.PubMedGoogle Scholar
  60. 59.
    Ferrario F, Tadros MT, Napodano P, Sinico RA, Fellin G, D’Amico G: Critical re-evaluation of “idiopathic” crescentic glomerulonephritis. Clin Nephrol 41: 1–9, 1994.PubMedGoogle Scholar
  61. 60.
    Pusey CD, Lockwood CM: Autoimmunity in rapidly progressive glomerulonephritis. Kidney Int 35: 929–937, 1989.PubMedCrossRefGoogle Scholar
  62. 61.
    Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235–238, 1979.PubMedCrossRefGoogle Scholar
  63. 62.
    Guillevin L, Fain O, Lhote F, Jarrouse B, Le Thi Huong D, Bussel A, Leon A: Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. Arthritis Rheum 35: 208–215, 1992.PubMedCrossRefGoogle Scholar
  64. 63.
    Fort JG, Abruzzo JL: Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis Rheum 31: 1194–1198, 1988.PubMedCrossRefGoogle Scholar
  65. 64.
    Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337: 1137–1139, 1991.PubMedCrossRefGoogle Scholar
  66. 65.
    Tuso P, Moudgil A, Hay J, Goodman D, Kamil E, Koyyana R, Jordan SC: Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 20: 504–508, 1992.PubMedGoogle Scholar
  67. 66.
    Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341: 1620–1622, 1993.PubMedCrossRefGoogle Scholar
  68. 67.
    Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliviera DGB, Lockwood CM, Waldmann H: Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 323: 250–254, 1990.PubMedCrossRefGoogle Scholar
  69. 68.
    Guillevin L, Llote F, Sauvaget F, Rossi F, Levallois D, Pourrat J, Christoforov B, Trepo C: Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 53: 334337, 1994.Google Scholar
  70. 69.
    Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS: Surgical pathology of the lung in Wegener’s granulomatosis. Am J Surg Pathol 15: 315–333, 1991.PubMedCrossRefGoogle Scholar
  71. 70.
    Bosch X, Mirapeix E, Font J, Cervera R, Ingelmo M, Khamashta MA, Revert L, Hughes GRV, Urbano-Marquez A: Anti-myeloperoxidase autoantibodies in patient with necrotizing glomerular and alveolar capillaritis. Am J Kidney Dis 20: 231–239, 1992.PubMedGoogle Scholar
  72. 71.
    Haworth SJ, Savage CO, Carr D, Hughes JMB, Rees AJ: Pulmonary hemorrhage complicating Wegener’s granulomatosis and microscopic polyarteritis. Br Med J 290: 1775 1778, 1985.Google Scholar
  73. 72.
    Imoto EM, Lombard CM, Sachs DP: Pulmonary capillaritis and hemorrhage: a clue to the diagnosis of systemic necrotizing vasculitis. Chest 96: 927–928, 1989.PubMedCrossRefGoogle Scholar
  74. 73.
    Cupps TR: Cyclophosphamide: to pulse or not to pulse? Am J Med 89: 399–402, 1990.PubMedCrossRefGoogle Scholar
  75. 74.
    Hoffman GS, Leavitt RY, Fleischer TA, Minor JR, Fauci AS: Treatment of Wegener’s granulomatosis with intermittent high dose intravenous cyclophosphamide. Am J Med 89: 403410, 1990.Google Scholar
  76. 75.
    Genereau T, Lortholary O, Leclerq P, Grenet D, Tubery M, Sicard D, Caubarrere I, Guillevin L: Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of pulse intravenous high-dose regimen in four patients. Br J Rheumatol 33: 959–962, 1994.PubMedCrossRefGoogle Scholar
  77. 76.
    Gross WL, Rasmussen N: Treatment of Wegener’s granulomatosis: the view from two non-nephrologists. Nephrol Dial Transplant 9: 1219–1225, 1994.PubMedGoogle Scholar
  78. 77.
    Boumpas DT, Austin HA III, Vaughan EM, Klfppel JH, Steinberg AD, Yarboro CH, Balow JE: Severe lupus nephritis: controlled trial of pulse methylprednisolone versus two different regimens of pulse cyclophosphamide. Lancet 340: 741–745, 1992.PubMedCrossRefGoogle Scholar
  79. 78.
    DeVita S, Neri R, Bombardieri S: Cyclophosphamide pulses in the treatment of rheumatic diseases: an update. Clin Exp Rheumatol 9: 179–193, 1991.Google Scholar
  80. 79.
    Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis (letter). Ann Intern Med 114: 430–431, 1991.CrossRefGoogle Scholar
  81. 80.
    Haga HJ, D’Cruz D, Asherson R, Hughes GR: Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 51: 885–888, 1992.PubMedCrossRefGoogle Scholar
  82. 81.
    Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM: Cyclophosphamide pulse therapy in Wegener’s granulomatosis. Nephrol Dial Transplant 6: 531–535, 1991.PubMedCrossRefGoogle Scholar
  83. 82.
    Kunis CL, Kiss B, Williams G, D’Agati V, Appel GB: Intravenous “pulse” cyclophosphamide therapy of crescentic glomerulonephritis. Clin Nephrol 37: 1–7, 1992.PubMedGoogle Scholar
  84. 83.
    Pall AA, Luqmani RA, Adu D, Richards N, Howie AJ, Emery P, Michael J, Bacon PA: Controlled trial of pulse cyclophosphamide (PCY) and prednisolone (PP) versus continuous cyclophosphamide (CCY) and prednisolone (CP) in the treatment of systemic vasculitis (abstract). J Am Soc Nephrol 3: 317, 1992.Google Scholar
  85. 84.
    Pusey CD, Rees AJ, Evans D, Peters DK, Lockwood CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40: 757–763, 1991.PubMedCrossRefGoogle Scholar
  86. 85.
    Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K, Dyck R, and the Canadian Apheresis Study Group: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. Am J Kidney Dis 20: 261–269, 1992.Google Scholar
  87. 86.
    Glockner WM, Sieberth HG, Wichmann HE, Backes E, Bambauer R, Boesken WH, Bohle A, Daul A, Graben N, Keller F, Klehr HU, Kohler H, Metz U, Schultz W, Thoenes W, Vlaho M: Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multicenter study. Clin Nephrol 29: 1–8, 1988.PubMedGoogle Scholar
  88. 87.
    Hind CR, Paraskevakou H, Lockwood CM, Evans DJ, Peters DK, Rees AJ: Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1: 263–265, 1983.PubMedCrossRefGoogle Scholar
  89. 88.
    Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK: Relapses in Wegener’s granulomatosis: the role of infection. Br Med J 281: 836–838, 1980.PubMedCrossRefGoogle Scholar
  90. 89.
    Weiss DJ, Greenfield JW Jr, O’Rourke KS, McCune WJ: Systemic cytomegalovirus infection mimicking an exacerbation of Wegener’s granulomatosis. J Rheumatol 20: 155–157, 1993.PubMedGoogle Scholar
  91. 90.
    DeRemee RA: The treatment of Wegener’s granulomatosis with trimethaprim-sulfamethoxazole: illusion or vision? Arthritis Rheum 31: 1068–1074, 1988.PubMedCrossRefGoogle Scholar
  92. 91.
    Valeriano-Marcet J, Spiera H: Treatment of Wegener’s granulomatosis with sulfamethoxazole—trimethaprim. Arch Intern Med 151: 1649–1652, 1991.PubMedCrossRefGoogle Scholar
  93. 92.
    Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366–369, 1993.PubMedCrossRefGoogle Scholar
  94. 93.
    Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Am J Med 83: 1–9, 1989.CrossRefGoogle Scholar
  95. 94.
    Levy M, Broyer M, Habib R: Pathology and immunopathology of Schönlein—Henoch glomerulonephritis. In: P Kincaid-Smith, AJF d’Apice, RC Atkins, eds, Progress in Glomerulonephritis. John Wiley and Sons, New York, p 261, 1979.Google Scholar
  96. 95.
    Kauffmann RH, Herrmann WA, Meyer CJ, Daha MR, Van Es LA: Circulating IgA-immune complexes in HenochSchönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med 69: 859–866, 1980.PubMedCrossRefGoogle Scholar
  97. 96.
    Meadow SR: The prognosis of Henoch Schoenlein nephritis. Clin Nephrol 9: 87–90, 1978.PubMedGoogle Scholar
  98. 97.
    Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantier C: Prognosis of Henoch—Schönlein nephritis in children. Br Med J 2: 11–14, 1977.PubMedCrossRefGoogle Scholar
  99. 98.
    Ilan Y, Naparstek Y: Schönlein—Henoch syndrome in adults and children. Semin Arthritis Rheum 21: 103–109, 1991.PubMedCrossRefGoogle Scholar
  100. 99.
    Cameron JS: The nephritis of Schönlein—Henoch purpura: current problems. In: P Kincaid-Smith, AJF d’Apice, RC Atkins, eds, Progress in Glomerulonephritis. John Wiley and Sons, New York, p 283, 1979.Google Scholar
  101. 100.
    Hall RP, Lawley TJ, Heck JA, Katz SI: IgA-containing circulating immune complexes in dermatitis herpetiformis, Henoch—Schönlein purpura, systemic lupus erythematosus and other diseases. Clin Exp Immunol 40: 431–437, 1980.PubMedGoogle Scholar
  102. 101.
    Fogazzi GB, Pasquali S, Moriggi M, Casanova S, Damilano I, Mihatsch MJ, Zucchelli P, Ponticelli C: Long-term outcome of Schonlein-Henoch nephritis in the adult. Clin Nephrol 31: 60–66, 1989.PubMedGoogle Scholar
  103. 102.
    Austin HA III, Balow JE: Henoch—Schönlein nephritis: prognostic features and the challenge of therapy. Am J Kidney Dis 2: 512–520, 1983.PubMedGoogle Scholar
  104. 103.
    Lee HS, Koh HI, Kim MJ, Rha HY: Henoch—Schoenlein nephritis in adults: a clinical and morphological study. Clin Nephrol 26: 125–130, 1986.PubMedGoogle Scholar
  105. 104.
    Goldstein AR, White RHR, Akuse R, Chantier C. Longterm follow-up of childhood Henoch—Schönlein nephritis. Lancet 339: 280–282, 1992.PubMedCrossRefGoogle Scholar
  106. 105.
    Hurley RM, Drummond KN: Anaphylactoid purpura nephritis: clinicopathological correlations. J Pediatr 81: 904911, 1972.Google Scholar
  107. 106.
    White RH, Cameron JS, Trounce JR. Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome. Br Med J 2: 853860, 1966.Google Scholar
  108. 107.
    Michael AF, Vernier RL, Drummond KN, Levitt JI, Herdman RC, Fish AJ, Good RA: Immunosuppressive therapy of chronic renal disease. N Engl J Med 276: 817–828, 1967.PubMedCrossRefGoogle Scholar
  109. 108.
    Medical Research Council Working Party: Controlled trial of azathioprine and prednisone in chronic renal disease. Br Med J 2: 239–241, 1971.CrossRefGoogle Scholar
  110. 109.
    Fillastre JP, Morel-Maroger L, Richet G: Schönlein—Henoch purpura in adults. Lancet 1: 1243–1244, 1971.PubMedCrossRefGoogle Scholar
  111. 110.
    Brown CB, Wilson D, Turner D, Cameron JS, Ogg CS, Chantier C, Gill D: Combined immunosuppression and anticoagulation in rapidly progressive glomerulonephritis. Lancet 2: 1166–1172, 1974.PubMedCrossRefGoogle Scholar
  112. 111.
    Cameron JS, Gill D, Turner DR, Chantier C, Ogg CS, Vosnides G, Williams DG: Combined immunosuppression and anti-coagulation in rapidly progressive glomerulonephritis. Lancet 2: 923–925, 1975.PubMedCrossRefGoogle Scholar
  113. 112.
    Rose GM, Cole BR, Robson AM: The treatment of severe glomerulopathies in children using high dose intravenous methylprednisolone pulses. Am J Kidney Dis 1: 148–156, 1981.PubMedGoogle Scholar
  114. 113.
    McKenzie PE, Taylor AE, Woodroffe AJ, Seymour AE, Chan YL, Clarkson AR: Plasmapheresis in glomerulonephritis. Clin Nephrol 12: 97–108, 1979.PubMedGoogle Scholar
  115. 114.
    Kauffmann RH, Houwert DA: Plasmapheresis in rapidly progressive Henoch—Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes. Clin Nephrol 16: 155–160, 1981.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • James E. Balow
    • 1
  • Howard A. AustinIII
    • 1
  1. 1.Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney DiseaseNational Institutes of HealthBethesdaUSA

Personalised recommendations